PLX (Protalix BioTherapeutics) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
54 GF Score
Price $2.34
GF Value $2.20
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Protalix BioTherapeutics Quality Rank Related Terms

PLX
54GF Score
Protalix BioTherapeutics Inc PLX
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for PLX:

  • Quality Rank:
  • GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score

Get the complete analysis for PLX

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$2.20
GF Value